Why do you need an effective option after tamoxifen therapy?

After adjuvant tamoxifen treatment, risks of recurrence and mortality remains substantial^1,2

• More than 1 in 2 recurrences develop following surgery and 5 years of adjuvant tamoxifen therapy in women with hormone receptor positive breast cancer¹
• A significant percentage of patients receiving adjuvant tamoxifen will have died within 10 years from initial diagnosis—39% of node-positive patients and 21% of node-negative patients²

FEMARA^® (letrozole) is the first and only extended adjuvant therapy approved for use after 5 years of treatment with tamoxifen^3-5

After 5 years of tamoxifen treatment, FEMARA^® can help to protect postmenopausal women with HR+ breast cancer from recurrence, including distant metastases^3,6

To learn more about FEMARA^® in the extended adjuvant setting, see:

MA-17 Trial Design

MA-17 Efficacy Results

MA-17 Safety Results

Extended adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.

Click here for Important Safety Information for FEMARA^®.

References: 1. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer [abstract]. J Clin Oncol. 2004;22(14S):1. Abstract 847. 2. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467. 3. FEMARA^® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009. 4. Arimidex^® (anastrazole) [summary of product characteristics]. Luton, UK: AstraZeneca UK Limited; 2007. 5. Aromasin^® (exemestane) [summary of product characteristics]. Sandwich, UK: Pharmacia Ltd; 2008. 6. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.